Equillium Stock

Equillium Enterprise Value

The Enterprise Value (EV) of Equillium (EQ) as of Aug 12, 2026 is 100.03 M USD. In the previous year, Enterprise Value (EV) was 107.74 M USD — a change of -7.15% (lower).

Enterprise Value

100.03 MUSD

YoY

-7.15%

Last updated:

Enterprise Value (EV) of Equillium is 2026 100.03 M USD. Enterprise Value (EV) of Equillium was 2025 107.74 M USD. It decreases by -7.15% lower compared to the previous year.
Access this data via the Eulerpool API

Equillium Stock analysis

What does Equillium do? Equillium Inc is an emerging biotechnology company specializing in the research and development of therapies for the treatment of inflammatory and autoimmune diseases. The company was founded in 2017 by a group of experienced biotech entrepreneurs who aim to develop innovative and effective treatment methods to improve patients' quality of life. Equillium's business model focuses on the discovery and development of new therapies based on the modulation of the CD6 signaling pathway, a central regulator of the immune system. Equillium's technology aims to modulate the immune system to suppress an inflammatory response associated with autoimmune and other inflammatory diseases. The company collaborates closely with leading university research laboratories and experts in the field to develop effective therapies. Equillium targets a wide range of disease areas, including autoimmune diseases such as lupus, psoriasis, and Crohn's disease. The company has also developed a program to treat COVID-19, aiming to reduce the immune-mediated inflammatory response associated with severe cases of COVID-19. Equillium's product portfolio includes EQ001, a monoclonal antibody used for the treatment of lupus and other autoimmune diseases. EQ001 blocks the CD6 signaling pathway, thereby reducing inflammatory responses that attack healthy tissues in the body. The company is also working on developing a novel platform technology to explore additional therapy options based on the CD6 signaling pathway. Equillium has a strong funding base and is supported by some of the most renowned biotech investors. The company has a comprehensive pipeline of potential therapies that are intended to address a variety of indications in the future. Overall, Equillium's advanced biotechnological research and development have contributed to the discovery of new and effective ways to treat inflammatory and autoimmune diseases. The company is well-positioned to expand in this area of medicine and improve therapy options for patients worldwide. Equillium is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Equillium stock

Enterprise Value (EV) of Equillium is 100.03 M USD in 2026.

Enterprise Value (EV) of Equillium changed from 107.74 M USD to 100.03 M USD, representing a -7.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Equillium since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Equillium with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Equillium

All Key Metrics — Equillium